非酒精性脂肪性肝炎肝硬化发病机制研究进展与展望

doi:10.3969/j.issn.1672-5069.2018.02.005

Abstract

Chi Zhaochun. Pathogenesis of nonalcoholic steatohepatitis and cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 166-169.

[1] European Association for the Study of the Liver (EASL);European Association for the Study of Diabetes (EASD);European Association for the Study of Obesity(EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obes Facts,2016,9:65-90.
[2] Lonardo A,Ballestri S,Marchesini G,et al.Nonalcoholic fatty liver disease:a precursor of the metabolic syndrome. Dig Liver Dig,2015,47:181-190.
[3] Eslam M,Geoyge J.Genetic and epigenetic mechanisms of NASH. Hepatol Int,2016,10:394-406.
[4] Xiong J,Wang J,Huang J,et al.Non-alcoholic steatohepatitis-related liver cirrhosis is increasing in China :a ten-year retrospective study. Clinics (Sa0Paulo),2015,70:563-568.
[5] Hartieb M,Baranski K,Zejda J,et al.Non-alcoholic fatty liver (NAFL) and advanced fibrosis in the elderly:results from a community-based Polish survey. Liver Int,2017,[Epub ahead of print].
[6] Kabbany MN,Conjeevaram Selvakumar PK,Watt K,et al.Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States:analysis of National Helath and Nutrition Examination Survey Data. Am J Gastroenterol,2017,112:581-587.
[7] Xong J,Wang J,Huang J,et al.Non-alcoholic steatohepatitis-related liver cirrhosis is increasing in China:a ten-year retrospective study. Clinics (Sao Paulo),2015,70:563-568.
[8] Arab JP,Barrera F,Gallego C,et al.High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type2 diabetic patients. Ann Hepatol,2016,15:721-728.
[9] Bhadoria AS,Kedarisetty CK,Bihari C,et al. Impact of family history of metabolic traits on severity of non-alcoholic steatohepatitis related cirrhosis:A cross-sectional study. Liver Int,2017 Feb 23,[Epub ahead of print].
[10] Oxley SM,Sackstein R.Detect of an L-selectin ligand on a hematopoietic progenitor cell line. Blood,1994,84:3299-3306.
[11] Alves CS, Burdick MM,Thomas SN,et al.The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion. Am J Physiol,Cell Physiol,2008,294:C907-916.
[12] Patouraux S,Rousseau D,Bonnafous S,et al. CD44 is a key player in non-alcoholic steatohepatitis. J Hepatol,2017 Mar 16,[Epub ahead of print].
[13] Laish I,Mannasse-Green B,Hadary R,et al.Telomere dysfunction in nonalcoholic fatty liver disease and cryptogenic cirrhosis. Cytogenrt Genome Res,2016,150:93-99.
[14] Petta S,Valenti L,Svegliati-Baroni G,et al.Fibronectin type III domain-containing protein 5 re3480AG polymorphism,irisin,and liver fibrosis in patients with nonslcoholic fatty liver disease. J Clin Endocrinol Metab,2017,[Epub ahead of print].
[15] Nakajima S,Tanaka H,Sawada K,et al.Polymorphism of receptor-type tyrosine-protein phosphatase delta gene in the development of non-alcoholic fatty liver disease. J Gastroenterol Hepatol,2017,[Epub ahead of print].
[16] Kim SG,Kim BK,Kim K,et al.Bile acid nuclear receptor Farnesoid X receptor:therapeutic target for noncoholic fatty liver disease.Endocrinol Metab (Seoul),2016,31:500-504.
[17] Zhu Y,Liu H,Zhang M,et al.Fatty liver diseases,bile acids,and FXR. Acta Pharm Sin B,2016,6:409-412.
[18] de la Garza RG,Morales-Garza LA,Martin-Estal I,et al. Insulin-like growth factor-1 deficiency and cirrhosis establishment. Clin Med Res,2017,9:233-247.
[19] Chishima S,Kogiso T,Matsushita N,et al.The relationship between the growth hormone/insulin-like growth factor system and the histological features of noncoholic fatty liuver disease. Intern Med,2017,56:473-480.
[20] Chimen M,Yates CM,McGettrick HM,et al. Monocyte subsets coregulate inflammatory responses by integrated signaling through TNF and IL-6 at the endothelial cell interface. J Immunol,2017,198:2834-2843.

Pathogenesis of nonalcoholic steatohepatitis and cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.
[2]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[3]	Ren Yufei, Chen Xiaoqing, Kong Weizong, et al.. Effect of salvianolic acid B on autophagy in nonalcoholic fatty liver disease cell model in vitro [J]. Journal of Practical Hepatology, 2019, 22(6): 804-807.
[4]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.
[5]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[6]	Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels [J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.
[7]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[8]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[9]	Liu Li, Yang Lie, Chen Haiyang, et al.. Changes of hemodynamics after splenectomy combined with pericardial devascularization in patients with cirrhotic portal hypertention complicated by splenic artery steal syndrome [J]. Journal of Practical Hepatology, 2019, 22(6): 884-887.
[10]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[11]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[12]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[13]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[14]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[15]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.